This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Monday's Small-Cap Winners & Losers

The small-cap sector crawled beneath the struggling broad indices Monday despite surging names like XTL Biopharmaceuticals (XTLB - Get Report), which announced it began a phase IIb trial of Bicifadine for treatment of diabetic neuropathic (nervous-system-related) pain.

Shares of the Valley Cottage, N.Y., company were up 30.4% to $1.76.

InPlay Technologies (NPLA), based in Phoenix, climbed on word of a purchase-order renewal for its thiNcoder rotary-switch technology. The customer, a "leading supplier of products for the global sleep and respiratory markets," agreed to buy at least one million units through Duraswitch licensees over the next 18 months for a new line of positive-airway-pressure-therapy products. InPlay shares were leaping 15.2% to $1.74.

Elsewhere, management-services firm Versar (VSR - Get Report) bounced 2.8% after swinging to a fiscal fourth-quarter profit of $803,000, as well as posting a more-than-tripled full-year profit of $5.3 million, or 62 cents a share. Full-year sales soared 68.7% to $102.7 million. Shares of the Springfield, Va., company were trading at $8.94.

On the downside today, however, was Cardica (CRDC - Get Report), which slid 15.4% to $8.39 after A.G. Edwards cut the stock to sell from buy. The analyst said its shares spiked too high after last week's announcement of two pioneering closed-chest bypass surgeries using a Cardica device that automates the attachment of a blood vessel graft to a coronary artery during bypass surgery.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs